NRx Pharma reports FY2022 net loss $39.8M; advances NRX-101 trials, issues going concern warning

NRX Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.16

Net loss $39.8M for FY2022 vs $93.1M prior year; R&D $17.0M, G&A $27.4M.
Cash $20.1M at Dec 31, 2022; raised $2.9M in March 2023 registered direct offering.
DSMB cleared NRX-101 Phase 2b/3 trial for suicidal treatment-resistant bipolar depression; topline data expected 4Q2023.
FDA suggested broader outpatient indication for NRX-101; safety database of 1,500 patients required.
Going concern doubt: no revenue, $11M note to Streeterville Capital may require cash repayment; additional financing needed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

NRX Pharmaceuticals, Inc. reported financial results for full year and fourth quarter ended December 31, 2022.

Period: full year and fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, the Company announced its financial results for the full year and fourth quarter ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-039554

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.